Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Los Angeles Capital Management LLC purchased a new stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 33,932 shares of the company’s stock, valued at approximately $542,000.

Several other institutional investors and hedge funds also recently made changes to their positions in TRDA. US Bancorp DE purchased a new stake in Entrada Therapeutics during the 3rd quarter valued at $42,000. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics during the first quarter valued at $79,000. SG Americas Securities LLC purchased a new stake in shares of Entrada Therapeutics during the third quarter valued at $156,000. Allspring Global Investments Holdings LLC raised its position in Entrada Therapeutics by 427.6% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after buying an additional 11,965 shares during the last quarter. Finally, BayBridge Capital Group LLC bought a new position in Entrada Therapeutics during the 3rd quarter valued at about $464,000. Institutional investors own 86.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Oppenheimer lifted their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 6th. HC Wainwright lifted their price objective on Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th.

Insider Buying and Selling at Entrada Therapeutics

In related news, insider Natarajan Sethuraman sold 2,642 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $15.09, for a total value of $39,867.78. Following the completion of the transaction, the insider now owns 183,816 shares of the company’s stock, valued at approximately $2,773,783.44. This represents a 1.42 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, COO Nathan J. Dowden sold 1,904 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $15.07, for a total value of $28,693.28. Following the sale, the chief operating officer now directly owns 125,996 shares in the company, valued at approximately $1,898,759.72. This represents a 1.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 22,933 shares of company stock valued at $410,816. Company insiders own 7.59% of the company’s stock.

Entrada Therapeutics Price Performance

Shares of Entrada Therapeutics stock opened at $17.85 on Friday. The stock has a market capitalization of $667.95 million, a PE ratio of 11.23 and a beta of -0.26. Entrada Therapeutics, Inc. has a 1-year low of $10.75 and a 1-year high of $20.49. The company’s fifty day simple moving average is $16.76 and its 200-day simple moving average is $15.94.

Entrada Therapeutics Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.